The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy
Open accessAbstract
Mouse glioma 261 (Gl261) cells are used frequently in experimental glioblastoma therapy; however, no detailed description of the Gl261 tumor model is available. Here we present that Gl261 cells carry point mutations in the K‐ras and p53 genes. Basal major histocompatibility complex (MHC)I, but not MHCII, expression was detected in Gl261 cells. The introduction of interferon‐γ‐encoding genes increased expression of both MHCI and MHCII. A low amount of B7‐1 and B7‐2 RNA was detected in wild‐type cells, but cytokine production did not change expression levels. Gl261 cells were transduced efficiently by adenoviral vectors; the infectivity of retroviral vectors was limited. Low numbers of transplanted Gl261 cells formed both subcutaneous and intracranial tumors in C57BL/6 mice. The cells were moderately immunogenic: prevaccination of mice with irradiated tumor cells 7 days before intracranial tumor challenge prevented tumor formation in approximately 90% of mice. When vaccination was carried out on the day or 3 days after tumor challenge, no surviving animals could be found. In vitro‐growing cells were radiosensitive: less than 2 Gy was required to achieve 50% cell mortality. Local tumor irradiation with 4 Gy X‐rays in brain tumor‐bearing mice slowed down tumor progression, but none of the mice were cured off the tumor. In conclusion, the Gl261 brain tumor model might be efficiently used to study the antitumor effects of various therapeutic modalities, but the moderate immunogenicity of the cells should be considered. (Cancer Sci 2006; 97: 546 – 553)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
DeAngelis, L. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440207 · Cited by 1,663
Clonal expansion of p53 mutant cells is associated with brain tumour progression
Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavanee, W., & Vogelstein, B. (1992) · Nature · doi:10.1038/355846a0 · Cited by 670
Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality
Legler, J. M., Ries, L. A. G., Smith, M. A., Warren, J. L., Heineman, E. F., Kaplan, R. S., & Linet, M. S. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.16.1382 · Cited by 452
Trojan, J., Johnson, T. R., Rudin, S. D., Ilan, J., Tykocinski, M. L., & Ilan, J. (1993) · Science · doi:10.1126/science.8418502 · Cited by 329
Studies on the chemotherapy of experimental brain tumors: development of an experimental model.
Ausman, J. I., Shapiro, W. R., & Rall, D. P. (1970) · PubMed · Cited by 223
Re: Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality
Schechter, C. B. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2050 · Cited by 211
Zagzag, D., Salnikow, K., Chiriboga, L., Yee, H., Lan, L., Ali, M. A., Garcia, R., Demaria, S., & Newcomb, E. W. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700233 · Cited by 189
Cited by
Immune microenvironment of gliomas
Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D., & Kaminska, B. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.19 · Cited by 538
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells
Catalano, M., D'Alessandro, G., Lepore, F., Corazzari, M., Caldarola, S., Valacca, C., Faienza, F., Esposito, V., Limatola, C., Cecconi, F., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.016 · Cited by 293
Glioma: experimental models and reality
Lenting, K., Verhaak, R., ter Laan, M., Wesseling, P., & Leenders, W. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1671-4 · Cited by 287
Sattiraju, A., Kang, S., Giotti, B., Chen, Z., Marallano, V. J., Brusco, C., Ramakrishnan, A., Shen, L., Tsankov, A. M., Hambardzumyan, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.017 · Cited by 279
Metadata
- Authors
- Szatmári, T., Lumniczky, K., Désaknai, S., Trajcevski, S., Hídvégi, E. J., Hamada, H., & Sáfrány, G.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2006-05-26
- Volume
- 97
- Issue
- 6
- Pages
- 546-553
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2068797588
- Cited by
- 361
- References
- 37
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. https://app.cochat.ai/papers/10.1111/j.1349-7006.2006.00208.x
- The paper
- Szatmári, T., Lumniczky, K., Désaknai, S., Trajcevski, S., Hídvégi, E. J., Hamada, H., & Sáfrány, G. (2006). Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Science. https://doi.org/10.1111/j.1349-7006.2006.00208.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.